|
Sartorius Stedim Biotech SA
/ Key word(s): Annual Results
Aubagne, France | February 17, 2025
Sartorius Stedim Biotech releases Universal Registration Document 2024 Sartorius Stedim Biotech, a leading partner of the biopharma industry, today released its Universal Registration Document 2024 including the Annual Financial Report. The document is available at the following link: Financial calendar March 25, 2025 Annual Shareholders’ Meeting April 16, 2025 Publication of the first quarter results January to March 2025 July 22, 2025 Publication of the half-year results January to June 2025 October 16, 2025 Publication of the nine-month results January to September 2025 A profile of Sartorius Stedim Biotech Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2024, the company generated sales revenue of around 2.8 billion euros. Currently, more than 9,900 employees are working for customers around the globe. Visit our and follow us on . Contact Leona Malorny Head of External Communications 7
Dissemination of a Financial Wire News, transmitted by EQS Group. |
| Language: | English |
| Issuer: | Sartorius Stedim Biotech SA |
| Avenue de Jouques | |
| 13781 Aubagne | |
| France | |
| Phone: | |
| E-mail: | |
| Internet: | -stedim.com |
| ISIN: | FR0013154002 |
| EQS News ID: | 2086777 |
| End of Announcement - EQS News Service | |
|
|
2086777 17-Feb-2025 CET/CEST
